Gilead Sciences Inc. (NASDAQ:GILD) has announced it will be taking over HOOKIPA Pharma Inc. (NASDAQ:HOOK) for a consideration ...

HOOKIPA Pharma (HOOK) stock gains as Gilead Sciences agrees to acquire some of its antiviral assets for up to $10M. Read more ...

Gilead Sciences is paying $10 million for sole ownership of arenavirus immunotherapies for hepatitis B (HBV) and HIV ...

Drugmaker Gilead is adding to its promised investments in the U.S., vowing to spend another $11B on top of the $21B it has already committed to research, development and manufacturing.

Analysts expect Hookipa Pharma to post earnings of ($0.61) per share and revenue of $3.38 million for the quarter. Hookipa Pharma Trading Up 15.6 % HOOK opened at $1.48 on Wednesday.

Gilead gave the money to doctors who spoke at HIV Speaker Program events in the form of honoraria payments, meals and travel expenses, according to the U.S. Attorney's Office in Manhattan, which ...

Gilead Sciences agreed to pay $202 million to the U.S. government and various states to settle civil claims that the drugmaker used speaker programs to pay kickbacks to doctors to induce them to ...

This meant a mixed quarter for Gilead. On average, analysts were modeling $6.78 billion for revenue, but anticipating a lower per-share adjusted profit of $1.77. Annual profit guidance reduced ...

For the period, Gilead's revenue clocked in at $6.67 billion, essentially flat over the same quarter of 2024. The company attributed this to sales declines of COVID drug Veklury and oncology products.

Nikos Pekiaridis / NurPhoto via Getty Images Gilead Sciences missed first-quarter revenue estimates as sales of its COVID-19 and cancer drugs declined. The biopharma's profit got a lift from ...